180 Life Sciences logo

180 Life SciencesNASDAQ: ATNF

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 June 2017

Website:

http://180lifesciences.com

Next earnings report:

15 August 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$1.44 M
-99%vs. 3y high
3%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

-1.51
-101%vs. 3y high
9%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

after hours | Wed, 26 Jun 2024 22:58:20 GMT
$1.53-$0.01(-0.65%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$1.68-

Revenue

Revenue target

--
No data over the past 3 years

Revenue

Net income

--$1.07 M

Analysts recommendations

Total assets

Total liabilities

$3.44 M$4.40 M

Institutional Ownership

Included in screeners

Small cap companies
Stocks with price below SMA 200
Stocks with low beta
Analysts recommendations: buy
Growing shares outstanding

Similar companies

Salarius Pharmaceuticals logo

Salarius Pharmaceuticals (SLRX)

NeuBase Therapeutics logo

NeuBase Therapeutics (NBSE)

LogicMark logo

LogicMark (LGMK)

CohBar logo

CohBar (CWBR)

Aethlon Medical logo

Aethlon Medical (AEMD)

Seelos Therapeutics logo

Seelos Therapeutics (SEEL)

Virpax Pharmaceuticals logo

Virpax Pharmaceuticals (VRPX)

Nemaura Medical logo

Nemaura Medical (NMRD)

ATNF Latest News

Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?
InvestorPlace09 August 2023 Sentiment: POSITIVE

180 Life Sciences (NASDAQ: ATNF ) stock is climbing higher on Wednesday as the cannabis market undergoes a rally. The cannabis sector has been on the rise lately as several companies in it release earnings reports.

Penny Stock Investing, 3 High-Growth Industries to Watch
PennyStocks21 May 2023 Sentiment: POSITIVE

Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What type of business is 180 Life Sciences?

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

What sector is 180 Life Sciences in?

180 Life Sciences is in the Healthcare sector

What industry is 180 Life Sciences in?

180 Life Sciences is in the Biotechnology industry

What country is 180 Life Sciences from?

180 Life Sciences is headquartered in United States

When did 180 Life Sciences go public?

180 Life Sciences initial public offering (IPO) was on 27 June 2017

What is 180 Life Sciences website?

https://180lifesciences.com

Is 180 Life Sciences in the S&P 500?

No, 180 Life Sciences is not included in the S&P 500 index

Is 180 Life Sciences in the NASDAQ 100?

No, 180 Life Sciences is not included in the NASDAQ 100 index

Is 180 Life Sciences in the Dow Jones?

No, 180 Life Sciences is not included in the Dow Jones index

When does 180 Life Sciences report earnings?

The next expected earnings date for 180 Life Sciences is 15 August 2024